Sugi Predict

Sugi Predict / Compounds / SCHEMBL24697149

SCHEMBL24697149

SCHEMBL24697149

Cc1c(C(F)(F)F)ccc(N)c1F

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ MPL P40238 4/20 0.35
▸ TSHR P16473 2/20 0.34
▸ GLA P06280 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ FFAR4 Q5NUL3 2/20 0.34
▸ CYP3A4 P08684 2/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ PDE2A O00408 1/20 0.32
▸ AR P10275 1/20 0.31
▸ KDM1A O60341 1/20 0.31
▸ TP53 P04637 1/20 0.30
▸ THRB P10828 1/20 0.30
▸ ALOX15 P16050 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30709854 1.00 KIF11 (0.37) KIF11SMN1; SMN2MPLTSHRGLA
SCHEMBL27373919 0.83 MPL (0.38) KIF11SMN1; SMN2MPLTSHRGLA
SCHEMBL4827135 0.83 ALOX5AP (0.37) SMN1; SMN2TSHRCYP3A4PIK3CATP53
Hydrochloric Acid SCHEMBL28383638 0.81 MPL (0.37) KIF11SMN1; SMN2MPLTSHRGLA
SCHEMBL5356428 0.80 SMN1; SMN2 (0.37) KIF11SMN1; SMN2TSHRGLAPOLB
Ammonia Solution, Strong SCHEMBL28689091 0.80 TSHR (0.39) KIF11SMN1; SMN2TSHRGLAPOLB
SCHEMBL922455 0.79 KIF11 (0.41) KIF11SMN1; SMN2MPLTSHRGLA
SCHEMBL27585461 0.79 SMN1; SMN2 (0.38) SMN1; SMN2TSHRCYP3A4PIK3CAAR
SCHEMBL9144284 0.77 KIF11 (0.39) KIF11SMN1; SMN2MPLTSHRGLA
SCHEMBL17666333 0.77 CYP11B1 (0.34) KIF11MPLPDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062425-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2026-03-05 — — US disclosed
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS INC (US) 2025-11-13 — — US disclosed
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-09-11 — — US disclosed
US-12338256-B2 Aza-tetracyclic oxazepine compounds and uses thereof GENENTECH, INC. (US) 2025-06-24 — — US disclosed
US-20250179093-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2025049274-A2 TETRACYCLIC DERIVATIVES, COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
US-20240368186-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2024-11-07 — — US disclosed
US-20240299385-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS REWIND THERAPEUTICS NV (BE) 2024-09-12 — — US disclosed
WO-2024149389-A1 SUBSTITUTED BRIDGE RING INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 苏州泽璟生物制药股份有限公司 2024-07-18 — — WO disclosed
EP-4389751-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Kumquat Biosciences Inc. (US) 2024-06-26 — — EP disclosed
EP-4347558-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS ReWind Therapeutics NV (BE) 2024-04-10 — — EP disclosed
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. 2024-01-25 — — US disclosed
WO-2023215801-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-11-09 — — WO disclosed
WO-2023179629-A1 SUBSTITUTED BRIDGED RING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 苏州泽璟生物制药股份有限公司 2023-09-28 — — WO disclosed
WO-2023103906-A1 KRAS G12D INHIBITOR AND USE IN MEDICINE 贝达药业股份有限公司 2023-06-15 — — WO disclosed
WO-2022254027-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS REWIND THERAPEUTICS NV (BE) 2022-12-08 — — WO disclosed
WO-2022254027-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS REWIND THERAPEUTICS NV (BE) 2022-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179093-A1 KRAS MODULATORS KRAS, NRAS, HRAS KIF11 2230/4885SMN1; SMN2 3622/4885MPL 1155/4885
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS KIF11 1979/4885SMN1; SMN2 2585/4885MPL 388/4885
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS KIF11 1979/4885SMN1; SMN2 2585/4885MPL 388/4885
US-12338256-B2 Aza-tetracyclic oxazepine compounds and uses thereof AZI2, TET3, OXA1L KIF11 1148/4885SMN1; SMN2 2361/4885MPL 866/4885
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF AZI2, TET3, OXA1L KIF11 1148/4885SMN1; SMN2 2361/4885MPL 866/4885
US-20240299385-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS GPR3, GPR27, GPR65 KIF11 1307/4885SMN1; SMN2 802/4885MPL 3130/4885
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS KIF11 1979/4885SMN1; SMN2 2585/4885MPL 388/4885
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS KIF11 2277/4885SMN1; SMN2 2906/4885MPL 1378/4885
US-20260062425-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF KRAS, NRAS, HRAS KIF11 1470/4885SMN1; SMN2 1998/4885MPL 3804/4885
US-20240368186-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF AZI2, TET3, OXA1L KIF11 1148/4885SMN1; SMN2 2361/4885MPL 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.